Patient & Public Involvement & Engagement

We are ensuring patients and families are at the heart of the Centre’s work by engaging with the RD community, listening and taking action on their experience at all levels.

Research lead

Catherine Turner

Cathy Turner is Project Manager for DMD Care UK – working to reach consensus, harmonisation and implementation for the highest standard of care for DMD across the UK at the John Walton Muscular Dystrophy Research Centre at Newcastle University. Cathy also coordinated the TREAT-NMD Advisory Committee for Therapeutics (TACT) which is an expert committee of world-leading experts across all aspects of therapy development for rare NMDs. She has also been responsible for supporting the FP7-funded NeurOmics project with significant involvement in communications, data-sharing and ethics. Prior to this she was the communications officer for a biomarker discovery project in NMD. In addition, Cathy works closely with patient organisations on improving patient and family involvement in neuromuscular research and is also developing interactive digital tools to support children taking part in paediatric clinical trials. Cathy has a background in journal publishing with Elsevier Science and Emerald Insight and then worked as a science teacher for 5 years before joining the team at Newcastle University in 2010. She has a degree in biochemistry, a post-graduate teaching certificate in science and a Masters in Business Administration.

University lead

Dr Steven Blackburn - University of Birmingham

Steven is an Associate Professor in the Department of Applied Health Sciences, University of Birmingham. An applied health researcher, with specific expertise in PPIE.

Ms Christine Collins MBE

Ms. Christine Collins is a retired civil servant and advocate for rare disease, health, and social care. She was the founding Chair of the Northern Ireland Rare Disease Partnership and has held key roles, including Chair of the Patient and Client Council and current Chair of the Regulation and Quality Improvement Authority (RQIA).

Area Overview

Ensuring patients and their families are at the heart of decision-making in rare disease research.

A key challenge in rare disease research has been the insufficient emphasis on Patient and Public Involvement and Engagement (PPIE), particularly in ensuring that patients and their families are fully integrated into the decision-making processes. Traditionally, governance in medical research has focused on protecting vulnerable patients, often overlooking the critical role that people living with rare diseases (PLWRD) play in driving the research agenda. Historically, patient involvement has often been superficial, with researchers maintaining control, leaving out vital patient perspectives that could enhance every stage of the research process. This lack of involvement is particularly evident in clinical trials for rare diseases, where the unique knowledge and insights of PLWRD and their carers are too frequently missed.

WPA aims to transform this landscape by embedding PPIE at every level of the ARDT project. Our approach will centre on appointing PLWRD at the highest levels of governance, ensuring they are integral to decision-making. We will work to embed PPIE into each work package, promoting active involvement of patients in shaping research priorities and strategies. Our focus will also include researching patient expectations around the acceleration of rare disease translational research across the four UK nations and undertaking public engagement events to increase awareness and understanding of the challenges faced by PLWRD.

By placing patients at the heart of the research process, we aim to empower them to influence the direction of scientific advancements, leading to more relevant, impactful, and ethical research outcomes in rare diseases. This approach will not only ensure that the voices of patients and families are heard but also improve the overall quality and inclusiveness of the research, contributing to better patient outcomes and more sustainable research practices.

Interested in working with the team?

We are always looking for talented researchers, clinicians, and industry partners to join our efforts in accelerating rare disease trials. Whether you’re interested in research collaboration, clinical trial design, or patient engagement, we’d love to hear from you.